aTyr Pharma faces layoffs amid biotech sector funding crunch

9 million in cash, announced a drastic 60% workforce reduction in Q2 2026. This marks a brutal shift in biotech's financial landscape, eliminating many roles and impacting projects across the organization. Many biotech firms still possess significant cash reserves and promising pipelines, yet they are forced into severe workforce reductions to extend operational runways. Aura Biosciences also cut approximately 20% of its workforce in 2026, according to Fierce Biotech . Simultaneous, significant reductions at aTyr Pharma and Aura Biosciences mark a challenging period for early and mid-stage biotech firms navigating a tighter funding environment. The current biotech market prioritizes financial discipline and immediate viability over long-term speculative growth, likely leading to further consolidation and a more cautious investment environment. ATyr Pharma's Financial Strain ATyr Pharma ended June 30, 2026, with $58.9 million in cash, cash equivalents, restricted cash and investments,…